secwatch / observer
8-K filed July 22, 2024, 7:59 PM ET ticker LITS CIK 0001262104
other material confidence high sentiment negative materiality 0.95

Lite Strategy, Inc. (LITS): restructuring charge — MEI Pharma halts voruciclib, cuts workforce, CEO/CMO depart, evaluates wind-down

Lite Strategy, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David M. Urso

President and Chief Executive Officer
LITS · Lite Strategy, Inc.
Effective
2024-08-01
Successor
Justin J. File
Filed
July 22, 2024, 7:59 PM ET
David M. Urso, our President and Chief Executive Officer, and Richard G. Ghalie, M.D., our Chief Medical Officer, will be leaving the Company effective August 1, 2024.
Departed

Richard G. Ghalie

Chief Medical Officer
LITS · Lite Strategy, Inc.
Effective
2024-08-01
Filed
July 22, 2024, 7:59 PM ET
David M. Urso, our President and Chief Executive Officer, and Richard G. Ghalie, M.D., our Chief Medical Officer, will be leaving the Company effective August 1, 2024.
Appointed

Frederick W. Driscoll

Chairperson of the Company
LITS · Lite Strategy, Inc.
Effective
2024-07-22
Filed
July 22, 2024, 7:59 PM ET
The Board has appointed Frederick W. Driscoll as Chairperson of the Company.
Appointed (interim)

Justin J. File

Acting Chief Executive Officer
LITS · Lite Strategy, Inc.
Effective
2024-08-01
Filed
July 22, 2024, 7:59 PM ET
The Board has appointed Justin J. File, age 53, currently the Company’s Chief Financial Officer and Secretary, to serve in the additional capacity of Acting Chief Executive Officer (“Acting CEO”), effective as of August 1, 2024.
Departed

Charles V. Baltic III

Chairperson of the Board
LITS · Lite Strategy, Inc.
Effective
2024-07-22
Successor
Frederick W. Driscoll
Filed
July 22, 2024, 7:59 PM ET
Charles V. Baltic III, the current Chairperson of the Board, will also step down from the Board effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David M. Urso departed as President and Chief Executive Officer at Lite Strategy, Inc..

Action
leaving
Role
President and Chief Executive Officer
Exact text from the filing
David M. Urso, our President and Chief Executive Officer, and Richard G. Ghalie, M.D., our Chief Medical Officer, will be leaving the Company effective August 1, 2024.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Richard G. Ghalie departed as Chief Medical Officer at Lite Strategy, Inc..

Action
leaving
Role
Chief Medical Officer
Exact text from the filing
David M. Urso, our President and Chief Executive Officer, and Richard G. Ghalie, M.D., our Chief Medical Officer, will be leaving the Company effective August 1, 2024.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Frederick W. Driscoll was appointed as Chairperson of the Company at Lite Strategy, Inc..

Action
appointed
Role
Chairperson of the Company
Exact text from the filing
The Board has appointed Frederick W. Driscoll as Chairperson of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Justin J. File was appointed as Acting Chief Executive Officer at Lite Strategy, Inc..

Action
appointed
Role
Acting Chief Executive Officer
Exact text from the filing
The Board has appointed Justin J. File, age 53, currently the Company’s Chief Financial Officer and Secretary, to serve in the additional capacity of Acting Chief Executive Officer (“Acting CEO”), effective as of August 1, 2024.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Charles V. Baltic III departed as Chairperson of the Board at Lite Strategy, Inc..

Action
step down
Role
Chairperson of the Board
Exact text from the filing
Charles V. Baltic III, the current Chairperson of the Board, will also step down from the Board effective immediately.
View on SEC.gov
Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Lite Strategy, Inc. announced a restructuring with charges of approximately $5.8 million affecting the Company (reduction-in-force).

Type
restructuring
Charge
approximately $5.8 million
Affected area
the Company
Headcount
reduction-in-force
Exact text from the filing
the Company expects to incur personnel-related restructuring charges of approximately $5.8 million in connection with one-time employee termination costs, including severance and other benefits, which are expected to be recognized in the first quarter of fiscal 2025
View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Lite Strategy, Inc. filing history →

Source: SEC EDGAR
accession 0000950170-24-085347
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.